Project Grant HT9425261E296
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $500K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- Federal Grant Award Summary The University of Washington received a $498,600 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2026 through July 31, 2028. The award supports research investigating anti-dystrophin T cell responses in patients with Duchenne muscular dystrophy (DMD), a congressionally-directed medical research priority under the DHA's portfolio. Research will be conducted at the...
- The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...
- Federal Grant Award Summary The University of Washington's Office of Sponsored Programs received a $1.697 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective May 1, 2026 through April 30, 2029. The award supports research and development of low-volume resuscitants for burn treatment in austere conditions under the project titled "Radiant Star Low-Volume Resuscitants for Burn Treatment in...
- The Defense Health Agency (DHA) awarded the University of Washington a $543,285 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. This award supports research focused on transforming rhabdomyosarcoma treatment through the development and evaluation of new FDA-approved combination therapies. The project will be conducted at the University of Washington's Seattle, Washington location under the...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
- Federal Grant Award Summary The University of Washington received a $1,494,943 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective April 1, 2026 through March 31, 2029. The award funds research on "Biomaterial Strategies to Improve Specificity and Efficacy of CAR T Cell Therapy for Breast Cancer," conducted at the university's Seattle campus. This research initiative delivers basic and applied...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University a Project Grant valued at $834,915 under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2026, through April 30, 2028. The award supports the development of small molecules designed to disrupt TDP-43 (TAR DNA-binding protein 43) aggregation and restore protein function. This research addresses neurodegenerative disease mechanisms relevant to military health...
- This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $572,306 in funding to the University of Washington for a 3-year research project to develop "ENHANCED GENE THERAPY FOR DMD USING LARGER DYSTROPHINS AND LOWER VECTOR DOSES". The aim is to advance gene therapy approaches for treating Duchenne muscular dystrophy (DMD) by utilizing larger dystrophin gene constructs and reducing the required vector doses. The...
- Federal Grant Award Summary Children's Research Institute received a $777,659 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2028. The award supports research titled "Use of ProResolution and Restorative Pharmacology Approaches for DMD Therapy," focusing on the development of innovative therapeutic interventions for Duchenne muscular dystrophy (DMD). The...
- Federal Grant Award Summary The University of Pennsylvania received a $499,971 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) with an award date of September 30, 2026, and completion date of June 29, 2028. The project involves repurposing a cancer-approved drug to ameliorate Duchenne muscular dystrophy (DMD) pathology, representing a translational research initiative that applies existing oncology therapeutics to...